Last reviewed · How we verify
Marijuana
At a glance
| Generic name | Marijuana |
|---|---|
| Also known as | cannabis, THC, cannabis, THC, Cannabis, Active cannabis, Cannabis |
| Sponsor | New York State Psychiatric Institute |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- Career Training in Marijuana Dependence (Phase 2)
- Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs (Phase 1)
- Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Alzheimer's Disease and Cannabis Clinical Trial (DAZACANN) Open-Label Phase (Phase 1)
- A Multi-Centre, Tolerability Study of a Cannabidiol-enriched Cannabis Herbal Extract for Chronic Headaches in Adolescents: the CAN-CHA Trial (Phase 2)
- CANBiome: Pilot-Study for the Comparison of Biomarkers Between Regular Cannabis Users and Non-Users (NA)
- The Impact of Cannabis Edibles Packaging Descriptors on Consumer Appeal, Harm Perceptions and Willingness to Try: Packaging Imagery Experiment (NA)
- Brief Computerized Intervention for Reducing Adolescent Cannabis and Alcohol Use (NA)
- Measuring Acute Drug Demand in Humans II (EARLY/Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Marijuana CI brief — competitive landscape report
- Marijuana updates RSS · CI watch RSS
- New York State Psychiatric Institute portfolio CI